Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and Benefits

R Rulach; G G Hanna; K Franks; J McAleese; S Harrow

doi:10.1016/j.clon.2017.11.003

Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and Benefits

Clin Oncol (R Coll Radiol). 2018 Feb;30(2):101-109. doi: 10.1016/j.clon.2017.11.003. Epub 2017 Dec 6.

Authors

R Rulach¹, G G Hanna², K Franks³, J McAleese², S Harrow⁴

Affiliations

¹ Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK. Electronic address: [email protected].
² Department of Clinical Oncology, Cancer Centre, Belfast City Hospital, Belfast, UK; Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.
³ Leeds Cancer Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁴ Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.

PMID: 29223641
DOI: 10.1016/j.clon.2017.11.003

Abstract

In spite of recent improvements in both the technical delivery of radiotherapy and systemic therapy in the treatment of non-small cell lung cancer, local recurrence rates after radiotherapy remain a significant challenge. In the setting of local relapse after radiotherapy, treatments such as surgical resection or radiofrequency ablation are often not appropriate owing to disease and patient factors. Re-irradiation may be a potential treatment option. This overview considers the published evidence and potential treatment strategies.

Keywords: Lung cancer; radiotherapy; re-irradiation; retreatment.

Publication types

Review

MeSH terms

Aged
Carcinoma, Non-Small-Cell Lung / radiotherapy*
Female
Humans
Lung Neoplasms / radiotherapy*
Male
Middle Aged
Neoplasm Recurrence, Local / radiotherapy*
Re-Irradiation / methods*